WO2016041439A1 - Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci - Google Patents

Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci Download PDF

Info

Publication number
WO2016041439A1
WO2016041439A1 PCT/CN2015/088434 CN2015088434W WO2016041439A1 WO 2016041439 A1 WO2016041439 A1 WO 2016041439A1 CN 2015088434 W CN2015088434 W CN 2015088434W WO 2016041439 A1 WO2016041439 A1 WO 2016041439A1
Authority
WO
WIPO (PCT)
Prior art keywords
naringin
group
levocetirizine hydrochloride
pharmaceutical composition
hydrochloride
Prior art date
Application number
PCT/CN2015/088434
Other languages
English (en)
Chinese (zh)
Inventor
苏薇薇
焦豪妍
廖彦
李沛波
彭维
王永刚
Original Assignee
中山大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山大学 filed Critical 中山大学
Priority to US15/100,992 priority Critical patent/US20160303156A1/en
Priority to EP15842769.0A priority patent/EP3069723B1/fr
Publication of WO2016041439A1 publication Critical patent/WO2016041439A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Definitions

  • the present invention relates to a naringin pharmaceutical composition for use in relieving cough, phlegm and asthma, and a preparation thereof.
  • Cough and sputum are two common symptoms of respiratory diseases. They are closely related in pathology. Generally, coughing is more common, and phlegm is often coughing. Long-term unhealed may cause emphysema, bronchiectasis, and pulmonary heart disease. Cough variant asthma refers to a special type of asthma with chronic cough as the main or only clinical manifestation.
  • the most widely used antitussive drugs in pharmaceutical medicines include codeine phosphate and dextromethorphan hydrobromide.
  • Codeine phosphate is a central nervous system chemical widely used for coughing or catching cold.
  • Common adverse reactions are: psychopathy or fantasy; weak, slow or irregular breathing; heart rate is fast or slow, abnormal.
  • Uncommon adverse reactions convulsions, tinnitus, tremors, or uncontrolled muscle movements; urticaria; allergic reactions such as rash, rash, or swollen face; mental depression and muscle rigidity. Long-term applications can cause dependence. The tendency of the usual dose to cause dependence is weaker than other morphine drugs.
  • Typical symptoms are: goose bumps, loss of appetite, diarrhea, toothache, nausea and vomiting, runny nose, chills, sneezing, yawning, sleep disorders, stomach cramps, excessive sweating, weakness, heart rate, emotional agitation or unexplained causes Fever.
  • Dextromethorphan hydrobromide is also a commonly used central nervous chemical cough suppressant, which consumers can buy at pharmacies.
  • serious adverse reactions have occurred, especially the abuse.
  • the foreign patients have repeatedly reported that the capsules caused by excessive consumption of powdered dextromethorphan caused death.
  • the US Food and Drug Administration is always concerned about the abuse of dextromethorphan. And issued a warning not to abuse dextromethorphan.
  • the US Food and Drug Administration says that the correct use of dextromethorphan in small doses can safely and effectively suppress cold symptoms, but abuse can cause death and other serious adverse effects such as brain damage, seizures, loss of consciousness and irregular heartbeat.
  • Naringin has better antitussive, phlegm and asthma and has no drug dependence, and the side effects are minimal. Therefore, the development of a compound drug with better efficacy around naringin will have a good prospect of drug use.
  • the present invention provides a naringin pharmaceutical composition for cough, expectorant and asthma, and a preparation thereof.
  • the pharmaceutical composition consists of naringin and levocetirizine hydrochloride.
  • the preferred daily dosage of the composition is 27.5 to 275 mg of naringin and 1.25 to 12.5 mg of levocetirizine hydrochloride.
  • the pharmaceutical compositions can be formulated to be clinically acceptable, including dosage forms such as tablets, liquids, capsules, aerosols, and the like.
  • the adjuvant of the pharmaceutical composition preparation may be: starch, lactose, mannitol, calcium hydrogen phosphate, carboxymethyl starch or a salt thereof and a group substitute, dextrin, chitosan, polyvinylpyrrolidone, cellulose and derivatives thereof Or polyethylene glycol.
  • naringin and levocetirizine hydrochloride components in the pharmaceutical combination of the present invention have synergistic effects, and the efficacy of the composition is significantly better than that of naringin or levocetirizine hydrochloride alone.
  • the pharmaceutical composition of the present invention can treat wheezing caused by cough, expectoration and cough variant asthma, and
  • the pharmaceutical composition can be added to a conventional excipient, and can be prepared into a drug for relieving cough, phlegm and asthma, according to any conventional method, without causing side effects of lethargy, lethargy, nausea, and vomiting.
  • naringin is prepared according to daily dosage of 120mg
  • levocetirizine hydrochloride is prepared according to daily dosage of 6mg
  • composition (1) is based on daily dosage of naringin 27.5mg
  • hydrochloric acid Formulation (2) was prepared according to human daily dosage of naringin 27.5mg and levocetirizine hydrochloride 12.5mg
  • composition (3) group was based on human daily naringin 275mg, hydrochloric acid left Cetirizine 1.25mg was prepared
  • composition (4) group was prepared according to human daily naringin 275mg, levocetirizine hydrochloride 12.5mg
  • Instrument YLS-8A induces cough and asthma (Shandong Medical Science Equipment Station products).
  • naringin and levocetirizine hydrochloride were administered alone and had significant antitussive effects (P ⁇ 0.05 or 0.01 compared with the blank group); naringin and levocetirizine hydrochloride The drug combination also had a good antitussive effect, and the antitussive effect was significantly better than the naringin alone or the levocetirizine hydrochloride alone group, the difference was statistically significant (compared with the single administration group, P ⁇ 0.05 or 0.01).
  • the results demonstrate that the pharmaceutical composition has a good antitussive effect and is significantly superior to the respective individual administration groups.
  • mice Male and female, weighing 30-40g, were provided by Guangdong Medical Laboratory Animal Center.
  • naringin is prepared according to the daily dose of 120mg
  • levocetirizine hydrochloride is prepared according to the daily dose of 6mg
  • composition (1) group according to the daily dose of naringin 27.5mg, hydrochloric acid left West Formulation (2) was prepared according to human daily dosage of naringin 27.5mg and levocetirizine hydrochloride 12.5mg
  • composition (3) group was based on human daily naringin 275mg, hydrochloric acid left Cetirizine 1.25mg was prepared
  • composition (4) group was prepared according to human daily naringin 275mg, levocetirizine hydrochloride 12.5mg
  • Kunming mice male and female, were randomly divided into blank control group, ambroxol group, naringin group, levocetirizine hydrochloride, composition (1) ⁇ composition (5) group, 10 groups in each group. .
  • 0.2ml/10g was administered by continuous intragastric administration for 2 days, and 5% phenol red physiological saline 0.2ml/10g was intraperitoneally injected 30 minutes after the last administration. After 30 minutes, the mice were sacrificed and the trachea was separated, and a trachea from the thyroid cartilage to the tracheal branch was cut.
  • the test tube was placed in a test tube containing 3 ml of physiological saline, and 0.1 ml of a 15% sodium hydrogencarbonate solution was added.
  • the phenol red content was calculated from the phenol red standard curve. Standard curve: 0.1 ⁇ g/ml, 0.3 ⁇ g/ml, 0.5 ⁇ g/ml, 0.7 ⁇ g/ml, 1 ⁇ g/ml, 3 ⁇ g/ml, 5 ⁇ g/ml, and 10 ⁇ g/ml of phenol red standard solution were prepared. If the drug can increase the secretion function of the respiratory tract, it can increase the phenol red. The amount of excretion, so the measured phenol red content level, can compare the difference in drug drainage effect.
  • naringin and levocetirizine hydrochloride alone can significantly increase the phenol red excretion in mice (P ⁇ 0.05 or 0.01 compared with the blank group), with significant ⁇
  • the combination of naringin and levocetirizine hydrochloride also has a good effect on improving the phenol red excretion in mice, and the effect of increasing phenol red excretion in mice is significantly better than that in naringin alone.
  • the combination of levocetirizine hydrochloride alone the difference was statistically significant (P ⁇ 0.05 or 0.01 compared with the single administration group).
  • naringin prepared according to daily dosage of 120mg; levocetirizine hydrochloride
  • the dosage of the composition (1) is 27.5 mg of naringin and 1.25 mg of levocetirizine hydrochloride; the composition (2) is 27.5 mg of naringin and hydrochloric acid.
  • Cetirizine 12.5mg was prepared; composition (3) group was prepared according to human daily naringin 275mg, levocetirizine hydrochloride 1.25mg; composition (4) group according to human daily naringin 275mg, hydrochloric acid left Cetirizine was prepared in 12.5 mg; composition (5) was prepared according to human daily dosage of naringin 120 mg and levocetirizine hydrochloride 6 mg.
  • the excitation concentration of methacholine (MeCh) was from low to high, 100 mg 100 mg/L, 200 mg/L, 400 mg/L, 800 mg/L, and 1600 mg/L, respectively, and the Penh average value under the excitation of each concentration grade MeCh was recorded.
  • the Penh value at each MeCh excitation concentration was converted to the percentage of the Penh value at the time of physiological saline (NS) challenge, expressed as Penh%, as an evaluation index of AR.
  • Bronchoalveolar lavage and bronchoalveolar lavage (BALF) white blood cell differential count: After the AR measurement, guinea pigs were anesthetized with sodium pentobarbital 30 mg/kg, then the neck skin was cut and cut in the middle of the trachea. Small mouth, insert the tracheal tube. Bronchoalveolar lavage was performed with 5 mL of normal saline, and washed back and forth 3 times, and bronchoalveolar lavage fluid was collected. All bronchoalveolar lavage fluid was centrifuged at 1500 rpm for 10 min at 4 ° C, and the supernatant was stored at -80 ° C until use.
  • 2.6 lung tissue section Take the frozen part of the right lung tissue, routine fixation, dehydration, HE staining, observe the pathological changes of airway and lung tissue.
  • the number of coughs was significantly increased in the model group compared with the normal control group (P ⁇ 0.01).
  • each of the administration groups was able to reduce the number of coughs, which was statistically different from the model control group.
  • the number of coughs was significantly lower in the naringin and levocetirizine hydrochloride combination groups than in the naringin-administered group or the levocetirizine hydrochloride alone group, and the difference was statistically significant (with administration alone).
  • Group comparison P ⁇ 0.05 or 0.01).
  • the above results demonstrate that the pharmaceutical composition has a good antitussive effect on ovalbumin-induced cough and is superior to the antitussive effect of each individual administration.
  • the total number of white blood cells, lymphocyte neutrophils and total eosinophils were significantly higher in the model control group than in the normal control group (P ⁇ 0.01 compared with the normal control group); naringin, hydrochloric acid
  • the administration of levocetirizine alone significantly reduced the total number of white blood cells, lymphocytes, neutrophils and total eosinophils (P ⁇ 0.05 or 0.01 compared with the model group); naringin and dextran hydrochloride
  • the telithizine composition significantly reduced the total number of white blood cells, lymphocytes, neutrophils, and total number of eosinophils (P ⁇ 0.05 or 0.01 compared with the model group), and with naringin alone or hydrochloric acid.
  • naringin and levocetirizine hydrochloride were significantly better than that of Otto group.
  • the naringin group and the levocetirizine hydrochloride group improved significantly.
  • naringin 40g levocetirizine hydrochloride 2g.
  • naringin 40g levocetirizine hydrochloride 2g.
  • 2 g of levocetirizine hydrochloride and 156 g of starch were mixed, and then mixed with naringin, wet granulation, granules were dried, 2 g of micro-silica gel was added, mixed, and pressed into 1000 tablets to obtain tablets.
  • naringin 40g levocetirizine hydrochloride 2g.
  • levocetirizine hydrochloride 2g Take naringin 40g, levocetirizine hydrochloride 2g. First, levocetirizine hydrochloride 2g plus lactose 38g mixed, then add naringin, 118g starch mixed, wet granulation, granules dry, add 2g of micro-silica gel, mix, press into 1000 tablets, that is, tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition à base de naringine et sa préparation. La composition pharmaceutique se caractérise en ce qu'elle est constituée de naringine et de chlorhydrate de lévocétirizine, de préférence 27,5 à 275 mg de naringine et 1,25 à 12,5 mg de chlorhydrate de lévocétirizine. De préférence, le rapport en masse de la naringine au chlorhydrate de lévocétirizine est de 20:1. La composition pharmaceutique a de bons effets thérapeutiques contre la toux et la mucosité dues à diverses causes, ainsi que contre l'asthme tussif. L'efficacité de la composition pharmaceutique est nettement supérieure à l'efficacité de la naringine ou du chlorhydrate de lévocétirizine utilisé(e) seul(e).
PCT/CN2015/088434 2014-09-18 2015-08-28 Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci WO2016041439A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/100,992 US20160303156A1 (en) 2014-09-18 2015-08-28 Pharmaceutical composition comprising naringin and levocetirizine hydrochloride, and preparations thereof
EP15842769.0A EP3069723B1 (fr) 2014-09-18 2015-08-28 Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410479766.2 2014-09-18
CN201410479766.2A CN104224819B (zh) 2014-09-18 2014-09-18 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂

Publications (1)

Publication Number Publication Date
WO2016041439A1 true WO2016041439A1 (fr) 2016-03-24

Family

ID=52214301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/088434 WO2016041439A1 (fr) 2014-09-18 2015-08-28 Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci

Country Status (4)

Country Link
US (1) US20160303156A1 (fr)
EP (1) EP3069723B1 (fr)
CN (1) CN104224819B (fr)
WO (1) WO2016041439A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224819B (zh) * 2014-09-18 2016-08-17 中山大学 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂
JP6638947B1 (ja) * 2019-06-26 2020-02-05 日医工株式会社 保存安定性に優れたレボセチリジン医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1430967A (zh) * 2003-01-21 2003-07-23 中山大学 柚皮苷用于制备治疗急、慢性支气管炎的药物
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN104224819A (zh) * 2014-09-18 2014-12-24 中山大学 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038240A1 (fr) * 2008-09-30 2010-04-08 Panacea Biotec Limited Composition pharmaceutique comprenant du nimésulide et de la lévocétirizine
CN101543476B (zh) * 2009-05-05 2011-01-26 中山大学 一种柚皮苷固体分散体及其制备方法和应用
GB0921803D0 (en) * 2009-12-14 2010-01-27 Biocopea Ltd Drug composition and its use in therapy
CN103622905A (zh) * 2013-12-17 2014-03-12 中山大学 一种矫味柚皮苷口服溶液及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1430967A (zh) * 2003-01-21 2003-07-23 中山大学 柚皮苷用于制备治疗急、慢性支气管炎的药物
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN104224819A (zh) * 2014-09-18 2014-12-24 中山大学 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHOEPKE, N ET AL.: "The Inhibition by Levocetirizine and Fexofenadine of the Histamine-induced Wheal and Flare Response in Healthy Caucasian and Japanese Volunteers", ACTA DERM VENEREOL, 31 December 2013 (2013-12-31), pages 286 - 293, XP055327925, ISSN: 0001-5555 *

Also Published As

Publication number Publication date
EP3069723A4 (fr) 2017-08-09
EP3069723B1 (fr) 2018-04-18
EP3069723A1 (fr) 2016-09-21
CN104224819B (zh) 2016-08-17
US20160303156A1 (en) 2016-10-20
CN104224819A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
KR101480595B1 (ko) 기관지염 치료를 위하여 제약조성물 및 이를 만드는 제조방법
CN101549060B (zh) 一种含有麻黄的治疗支气管炎的药物及其制备方法
CN106138360A (zh) 一种中药组合物及其制备方法、应用
CN101322761B (zh) 一种治疗气管炎、支气管炎的药物及其制备方法
CN102805746A (zh) 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
CN107648468B (zh) 一种治疗慢性阻塞性肺疾病的中药组合物及其应用
WO2016041439A1 (fr) Composition pharmaceutique à base de naringine et de chlorhydrate de lévocétirizine, et préparation de celle-ci
WO2016041438A1 (fr) Composition pharmaceutique de naringine et de chlorhydrate de fexofénadine et sa préparation
WO2016019736A1 (fr) Extrait de schisandra pour traiter la toux et soulager les inflammations des voies respiratoires, son procédé de préparation et son utilisation
CN105535406A (zh) 一种防治畜禽呼吸道疾病的中药组合物
CN101647885B (zh) 治疗咳嗽的药物组合物
CN109394746A (zh) 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用
CN102716128A (zh) 一种治疗哮喘的药用组合物
CN104257803A (zh) 一种治疗打呼的药物组合物及其制备方法和用途
CN104225201A (zh) 一种治疗咳嗽的药物组合物
CN103961654B (zh) 一种白葡萄球菌片及其制备方法
US20080033010A1 (en) Combination therapy of erdosteine and beta-2 agonists for treating respiratory pathologies characterized by non reversible or partially reversible airway obstruction
CN114917287B (zh) 一种治疗过敏性哮喘的中药组合物，其制备方法和应用
CN112245435B (zh) 一种用于解救钩吻中毒的组合物及其应用
CN117018132B (zh) 一种用于治疗咳嗽变异性哮喘的中药
CN108125237A (zh) 一种镇咳祛痰抗炎的保健品及其制备工艺
CN109106714B (zh) 止咳、化痰和平喘的药物组合物及其制剂
CN116036199B (zh) 中药组合物在制备辅助治疗儿童慢性咳嗽的药物中的应用
RU2611383C2 (ru) Комбинированный препарат для устранения симптомов и лечения острых респираторных вирусных инфекций и гриппа
CN106215080A (zh) 一种含有盐酸丙卡特罗的治疗小儿支气管哮喘的药物组合物及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 15100992

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015842769

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015842769

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15842769

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE